The DOI matches its Crossref record.
Large intestine–targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection
Open accessAbstract
Both rectal and vaginal mucosal surfaces serve as transmission routes for pathogenic microorganisms. Vaccination through large intestinal mucosa, previously proven protective for both of these mucosal sites in animal studies, can be achieved successfully by direct intracolorectal (i.c.r.) administration, but this route is clinically impractical. Oral vaccine delivery seems preferable but runs the risk of the vaccine's destruction in the upper gastrointestinal tract. Therefore, we designed a large intestine–targeted oral delivery with pH-dependent microparticles containing vaccine nanoparticles, which induced colorectal immunity in mice comparably to colorectal vaccination and protected against rectal and vaginal viral challenge. Conversely, vaccine targeted to the small intestine induced only small intestinal immunity and provided no rectal or vaginal protection, demonstrating functional compartmentalization within the gut mucosal immune system. Therefore, using this oral vaccine delivery system to target the large intestine, but not the small intestine, may represent a feasible new strategy for immune protection of rectal and vaginal mucosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tissue-Resident Memory T Cells
Schenkel, J. M., & Masopust, D. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.007 · Cited by 1,059
“, 2001; Woodland and Kohlmeier, 2009), and at least for CD8 T cells, this may include NLTs that were not sites of infection (Hofmann and Pircher, 2011; Kaufman et al., 2008; Liu et al., 2006; Masopust et al., 2010; 2004; Zhu et al., 2012).”
BackgroundSynthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Managing diabetes with nanomedicine: challenges and opportunities
Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4477 · Cited by 613
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Current state and challenges in developing oral vaccines
Vela Ramirez, J. E., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 412
Nanoparticle approaches against bacterial infections
Gao, W., Thamphiwatana, S., Angsantikul, P., & Zhang, L. (2014) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1282 · Cited by 347
Biomaterials for Nanoparticle Vaccine Delivery Systems
Sahdev, P., Ochyl, L. J., & Moon, J. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1419-y · Cited by 310
Enteric Micromotor Can Selectively Position and Spontaneously Propel in the Gastrointestinal Tract
Li, J., Thamphiwatana, S., Liu, W., Esteban-Fernández de Ávila, B., Angsantikul, P., Sandraz, E., Wang, J., Xu, T., Soto, F., Ramez, V., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b04795 · Cited by 277
Polymeric nanoparticle drug delivery technologies for oral delivery applications
Pridgen, E. M., Alexis, F., & Farokhzad, O. C. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1018175 · Cited by 269
Metadata
- Authors
- Zhu, Q., Talton, J., Zhang, G., Cunningham, T., Wang, Z., Waters, R. C., Kirk, J., Eppler, B., Klinman, D. M., Sui, Y., Gagnon, S., Belyakov, I. M., Mumper, R. J., & Berzofsky, J. A.
- Venue
- Nature Medicine
- Published
- 2012-07-15
- Volume
- 18
- Issue
- 8
- Pages
- 1291-1296
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2093011718
- Cited by
- 185
- References
- 0
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.